Literature DB >> 20527935

Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma.

Douglas D Young1, Colleen M Connelly, Christoph Grohmann, Alexander Deiters.   

Abstract

MicroRNAs are a recently discovered new class of important endogenous regulators of gene function. Aberrant regulation of microRNAs has been linked to various human diseases, most importantly cancer. Small molecule intervention of microRNA misregulation has the potential to provide new therapeutic approaches to such diseases. Here, we report the first small molecule inhibitors and activators of the liver-specific microRNA miR-122. This microRNA is the most abundant microRNA in the liver and is involved in hepatocellular carcinoma development and hepatitis C virus (HCV) infection. Our small molecule inhibitors reduce viral replication in liver cells and represent a new approach to the treatment of HCV infections. Moreover, small molecule activation of miR-122 in liver cancer cells selectively induced apoptosis through caspase activation, thus having implications in cancer chemotherapy. In addition to providing a new approach for the development of therapeutics, small molecule modifiers of miR-122 function are unique tools for exploring miR-122 biogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20527935     DOI: 10.1021/ja910275u

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  81 in total

Review 1.  The role of microRNAs in colorectal cancer.

Authors:  Aaron J Schetter; Hirokazu Okayama; Curtis C Harris
Journal:  Cancer J       Date:  2012 May-Jun       Impact factor: 3.360

Review 2.  MicroRNAs and liver disease.

Authors:  Thomas A Kerr; Kevin M Korenblat; Nicholas O Davidson
Journal:  Transl Res       Date:  2011-02-02       Impact factor: 7.012

3.  Constructing and characterizing a bioactive small molecule and microRNA association network for Alzheimer's disease.

Authors:  Fanlin Meng; Enyu Dai; Xuexin Yu; Yan Zhang; Xiaowen Chen; Xinyi Liu; Shuyuan Wang; Lihua Wang; Wei Jiang
Journal:  J R Soc Interface       Date:  2013-12-18       Impact factor: 4.118

Review 4.  Prospects of miRNA-based therapy for pancreatic cancer.

Authors:  Priya Pai; Satyanarayana Rachagani; Chandrakanth Are; Surinder K Batra
Journal:  Curr Drug Targets       Date:  2013-09       Impact factor: 3.465

Review 5.  MicroRNAs and other non-coding RNAs as targets for anticancer drug development.

Authors:  Hui Ling; Muller Fabbri; George A Calin
Journal:  Nat Rev Drug Discov       Date:  2013-11       Impact factor: 84.694

Review 6.  MicroRNAs as novel regulators of stem cell fate.

Authors:  Eunhyun Choi; Eunmi Choi; Ki-Chul Hwang
Journal:  World J Stem Cells       Date:  2013-10-26       Impact factor: 5.326

Review 7.  The therapeutic potential of microRNAs: disease modulators and drug targets.

Authors:  Ailbhe M McDermott; Helen M Heneghan; Nicola Miller; Michael J Kerin
Journal:  Pharm Res       Date:  2011-08-05       Impact factor: 4.200

8.  MicroRNAs as mediators of cardiovascular disease: Targets to be manipulated.

Authors:  Seahyoung Lee; Eunhyun Choi; Sung-Man Kim; Ki-Chul Hwang
Journal:  World J Biol Chem       Date:  2015-05-26

Review 9.  MicroRNAs in colorectal cancer: role in metastasis and clinical perspectives.

Authors:  Shan Muhammad; Kavanjit Kaur; Rui Huang; Qian Zhang; Paviter Kaur; Hamza Obaid Yazdani; Muhammad Umar Bilal; Jiang Zheng; Liu Zheng; Xi-Shan Wang
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

10.  A Macrocyclic Peptide Ligand Binds the Oncogenic MicroRNA-21 Precursor and Suppresses Dicer Processing.

Authors:  Matthew D Shortridge; Matthew J Walker; Tom Pavelitz; Yu Chen; Wen Yang; Gabriele Varani
Journal:  ACS Chem Biol       Date:  2017-05-02       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.